The Latest Analyst Ratings for Cormedix
Portfolio Pulse from Benzinga Insights
Cormedix (NASDAQ:CRMD) has received mostly bullish ratings from analysts in the last quarter, with no bearish or indifferent ratings. The average 12-month price target for the stock is $12.6, representing a 13.1% decrease from the previous average price target of $14.50.
August 10, 2023 | 2:01 pm
News sentiment analysis
Sort by:
Ascending
NEUTRAL IMPACT
Cormedix has received mostly bullish ratings from analysts, but the average 12-month price target has decreased by 13.1%.
While Cormedix has received mostly bullish ratings from analysts, the decrease in the average 12-month price target could indicate a potential slowdown in the stock's growth. This could lead to a neutral short-term impact on the stock's price.
CONFIDENCE 90
IMPORTANCE 75
RELEVANCE 100